Pharma
sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Most Viewed Abstracts



Your Article Summary

See Latest Articles
(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lundbeck provides update on NDA for Serdolect for the treatment of schizophreni
Lundbeck, 05/19/09

H. Lundbeck A/S announced that it has not yet received an action letter from the US Food and Drug Administration for the New Drug Application for Serdolect for the treatment of schizophrenia. The company anticipated receipt of the action letter on May 2009, the originally assigned Prescription Drug User Fee Act date. The FDA informed the company that they would receive the action letter as soon as possible.

Today in Regulatory Issues...keeping you current

Advisory Committee briefing materials for CRESTOR sNDA available on US FDA web site
AstraZeneca, 12/15/09

Sixteen Fired for Records Snooping
HealthDataManagement, 12/09/09

Watson Files FDA Application for Generic Rozerem
Watson Pharmaceuticals, 12/07/09

 See all of Regulatory Issues

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address